Bennett Selby Investments LP Has $1.81 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Bennett Selby Investments LP lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 105.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,975 shares of the company's stock after purchasing an additional 5,646 shares during the period. Zoetis accounts for 0.7% of Bennett Selby Investments LP's holdings, making the stock its 26th biggest holding. Bennett Selby Investments LP's holdings in Zoetis were worth $1,807,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ZTS. Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. lifted its holdings in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after buying an additional 166 shares during the period. Navigoe LLC acquired a new position in Zoetis in the fourth quarter valued at $30,000. Murphy & Mullick Capital Management Corp acquired a new position in Zoetis in the fourth quarter valued at $44,000. Finally, Asset Planning Inc acquired a new position in Zoetis in the fourth quarter valued at $58,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president now directly owns 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,188 shares of company stock valued at $367,289 over the last three months. Corporate insiders own 0.18% of the company's stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $170.15 on Friday. The firm's 50-day moving average price is $157.41 and its 200-day moving average price is $164.29. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The firm has a market capitalization of $75.75 billion, a P/E ratio of 31.11, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.38 earnings per share. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.18%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's payout ratio is presently 35.91%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ZTS. UBS Group dropped their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Stifel Nicolaus dropped their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Finally, Morgan Stanley dropped their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Zoetis currently has a consensus rating of "Buy" and an average target price of $212.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.